Eagle Strategies LLC Trims Stock Holdings in Johnson & Johnson $JNJ

Eagle Strategies LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 4.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,775 shares of the company’s stock after selling 167 shares during the quarter. Eagle Strategies LLC’s holdings in Johnson & Johnson were worth $577,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of JNJ. Brighton Jones LLC raised its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson during the first quarter worth approximately $218,000. GAMMA Investing LLC raised its stake in shares of Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after purchasing an additional 14,118 shares during the last quarter. USA Financial Formulas raised its stake in shares of Johnson & Johnson by 24.7% during the first quarter. USA Financial Formulas now owns 1,434 shares of the company’s stock worth $238,000 after purchasing an additional 284 shares during the last quarter. Finally, Bard Financial Services Inc. raised its stake in shares of Johnson & Johnson by 0.3% during the first quarter. Bard Financial Services Inc. now owns 100,317 shares of the company’s stock worth $16,637,000 after purchasing an additional 289 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. UBS Group set a $198.00 price target on Johnson & Johnson in a research note on Friday, October 3rd. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Morgan Stanley increased their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Finally, Bank of America increased their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $191.41.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.7%

Shares of JNJ stock opened at $190.97 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The stock has a market cap of $459.92 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.42 and a beta of 0.40. The business has a fifty day simple moving average of $178.01 and a 200-day simple moving average of $163.56. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter last year, the business posted $2.82 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.